Cargando…
Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial
OBJECTIVES: The objective of this trial was to investigate the safety and preliminary effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo in preventing HIV infection in women. DESIGN: This was a phase 2, randomized, double-blind, placebo-controlled trial. SE...
Autores principales: | Peterson, Leigh, Taylor, Doug, Roddy, Ronald, Belai, Ghiorghis, Phillips, Pamela, Nanda, Kavita, Grant, Robert, Clarke, Edith Essie Kekawo, Doh, Anderson Sama, Ridzon, Renee, Jaffe, Howard S, Cates, Willard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876601/ https://www.ncbi.nlm.nih.gov/pubmed/17525796 http://dx.doi.org/10.1371/journal.pctr.0020027 |
Ejemplares similares
-
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015) -
Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020) -
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020) -
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)